



African Access Initiative Insights:

The Promise, Potential, and Implications of Cancer Immunotherapies in Africa

Jennifer Dent, President & CEO
www.bvgh.org

Introduction to BVGH



Who We Are

BIO Ventures for Global Health (BVGH) is a nonprofit organization working at the crossroads of the private and public sectors to advance research and improve health.

What We Do

BVGH connects people, resources, and ideas across biotechnology and pharmaceutical companies, governments, and nonprofits to solve global health issues.

What We Do

Expand Access to Cancer Medicines and Technologies in Africa



African Access Initiative: Connecting Industry with African Leaders to Improve Cancer Care

Accelerate Research and Development (R&D) for Diseases of Poverty



WIPO Re:Search: Connecting Industry Assets and Researchers to Drive Neglected Disease R&D

Build Biomedical R&D Capacity in Low- and Middle-Income Countries (LMICs)



Fellowships and Equipment Donation: Connecting LMIC Researchers with Industry Expertise and Resources




Africa Pavilion: Connecting African Researchers with Global Life Science Leaders for Partnership Development

Africa's Cancer Crisis

Annual new cases and deaths due to cancer in Africa are predicted to **DOUBLE** by 2040

Cancer Incidence & Mortality, 2020-2040: Africa



Lung cancer: Africa's mortality to incidence ratio is 39% higher than North America's

Cervical cancer: rates are four times higher in Africa than in the USA

Breast cancer: African women are diagnosed with higher rates of triple-negative breast cancer than other ethnicities

Head & neck cancers: seventh most common cancer in Africans

Prostate cancer: leading cause of cancer mortality in African men

AAI Goals

**Establish
sustainable access
to cancer
medicines &
technologies**



**Strengthen
healthcare
infrastructure**



**Build clinical
oncology capacity**



**Address the cancer
data gap in Africa
through clinical
trials**




**Expand awareness
of cancer in Africa**



AAI Partners



Hospital Needs Assessment



Goal: Conduct needs assessments of AAI hospitals to define priorities and frame specific needs

Data include:

- Number of cancer patients
- Hospital's diagnostic capabilities and infrastructure
- Existing and needed medical equipment
- Cancer research and clinical trials capacity and interests
- Human resources capacity
- Cancer drugs used and needed

Diagnostic Capabilities



Capacity:

- Histology – H&E (82%)
- Immunohistochemistry (60%)
- Flow cytometry (50%)
- CT, ultrasound, x-ray (80-90%)
- MRI (60%)
- PET (8%)

Priority Needs:

- Capacity building: advanced pathology, histotechnology, flow cytometry
- Affordable and sustainable access to reagents
- Laboratory EQA
- Equipment: laboratories frequently face machine break-downs; access to basic and advanced instruments

Augmenting Diagnostic Capabilities



In-country fellowships to establish pathology SOPs and build expertise on new equipment in Rwanda



Specimen handling and processing best practices workshop & cancer patient sample referral system fellowship in Kenya



Advanced pathology workshop and webinar series for Côte d'Ivoire and Senegal

Clinical Oncology Capacity



Capacity:

- Oncology surgery (76%)
- Chemotherapy (74%)
- Brachytherapy (32%)
- External beam radiotherapy (34%)

Priority Needs:

- Capacity building: hands-on oncology surgery training & practice; oncology nursing; oncology pharmacy; radiotherapy
- Institutional tumor boards
- Equipment: infusion pumps; frequent machine-breakdowns

Building Clinical Oncology Capacity



Multidisciplinary management of prostate cancer workshop and prostate cancer surgery webinar series in Côte d'Ivoire



HDR brachytherapy and IMRT webinar series for medical physicists, RTTs, and radiation oncologists and oncology nursing webinar series in Nigeria



Multidisciplinary management of breast cancer workshop and gynecology oncology webinar series in Rwanda

Access to Cancer Drugs



Available Drugs:


- Chemotherapy (widely available)
- Hormonal therapy (available)
- Biological therapy (mAb therapies primarily available only to those patients who can cover the costs)

Priority Needs:

- Affordable access to high-quality cancer drugs
- Efficient supply chain
- Budgeting and drug forecasting guidance

Accelerating Access to Cancer Drugs

AAI Cancer Drug Access Program



Accelerating Access to Cancer Drugs



Cancer stakeholder meeting to define nationwide treatment guidelines



Request for proposals for 41 prioritized innovative and generic cancer drugs



AAI RFP at the state-level with leaders in 7 northern Nigerian states

Clinical Trial Capacity



Capacity:

- IRB/ERB (100%)
- Prior experience performing clinical trial (87%)
- Recipients of international or national research grants (90%)

Priority Needs:

- Lecture-based and practical experience and training

Building Clinical Trial Capacity



Fellowship to build clinical trial capacity in Kenya



Virtual and in-person clinical trial knowledge exchange program in Rwanda with Takeda



African Consortium for Cancer Clinical Trials (AC³T)

Increasing Awareness of Cancer



Nigerian breast cancer community event
– Biden Cancer Summit



Interview on Nigeria's *Arise News*



www.bvgh.org
jdent@bvgh.org